Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shom Goel

Showing results (21-30 of 70) with videos related to

Pageof 7
Sort By:
Future Oncology (London, England)|October 3, 2023
Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with HR+, HER2+ advanced breast cancer: plain language summary of the monarcHER studySara M Tolaney, Shom Goel, Adams Kusi Appiah, et al.
Trends in Cancer|March 29, 2025
Navigating life as an early career researcherShruti Bhatt, Yash Chhabra, Merav Cohen, et al.
Physiological Reviews|July 12, 2011
Normalization of the vasculature for treatment of cancer and other diseasesShom Goel, Dan G Duda, Lei Xu, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 16, 2011
Endothelial focal adhesion kinase mediates cancer cell homing to discrete regions of the lungs via E-selectin up-regulationSachie Hiratsuka, Shom Goel, Walid S Kamoun, et al.
The Oncologist|August 2, 2022
Targeting CDK4 and 6 in Cancer Therapy: Emerging Preclinical Insights Related to AbemaciclibSeth A Wander, Neil O'Brien, Lacey M Litchfield, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 22, 2010
C-X-C receptor type 4 promotes metastasis by activating p38 mitogen-activated protein kinase in myeloid differentiation antigen (Gr-1)-positive cellsSachie Hiratsuka, Dan G Duda, Yuhui Huang, et al.
Breast (Edinburgh, Scotland)|December 25, 2010
Rational use of trastuzumab in metastatic and locally advanced breast cancer: implications of recent researchShom Goel, Jacquie Chirgwin, Prudence Francis, et al.
BMC Cancer|March 24, 2021
Stereotactic radiotherapy for oligoprogressive ER-positive breast cancer (AVATAR)Reem Alomran, Michelle White, Melissa Bruce, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 22, 2012
TGF-β blockade improves the distribution and efficacy of therapeutics in breast carcinoma by normalizing the tumor stromaJieqiong Liu, Shan Liao, Benjamin Diop-Frimpong, et al.
Translational Oncology|November 23, 2020
Enhanced toxicity with CDK 4/6 inhibitors and palliative radiotherapy: Non-consecutive case series and review of the literatureSteven David, Gwo Ho, Daphne Day, et al.
Pageof 7

Showing results (21-30 of 70) with videos related to

Sort By:
Pageof 7
Future Oncology (London, England)|October 3, 2023
Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with HR+, HER2+ advanced breast cancer: plain language summary of the monarcHER studySara M Tolaney, Shom Goel, Adams Kusi Appiah, et al.
Trends in Cancer|March 29, 2025
Navigating life as an early career researcherShruti Bhatt, Yash Chhabra, Merav Cohen, et al.
Physiological Reviews|July 12, 2011
Normalization of the vasculature for treatment of cancer and other diseasesShom Goel, Dan G Duda, Lei Xu, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 16, 2011
Endothelial focal adhesion kinase mediates cancer cell homing to discrete regions of the lungs via E-selectin up-regulationSachie Hiratsuka, Shom Goel, Walid S Kamoun, et al.
The Oncologist|August 2, 2022
Targeting CDK4 and 6 in Cancer Therapy: Emerging Preclinical Insights Related to AbemaciclibSeth A Wander, Neil O'Brien, Lacey M Litchfield, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 22, 2010
C-X-C receptor type 4 promotes metastasis by activating p38 mitogen-activated protein kinase in myeloid differentiation antigen (Gr-1)-positive cellsSachie Hiratsuka, Dan G Duda, Yuhui Huang, et al.
Breast (Edinburgh, Scotland)|December 25, 2010
Rational use of trastuzumab in metastatic and locally advanced breast cancer: implications of recent researchShom Goel, Jacquie Chirgwin, Prudence Francis, et al.
BMC Cancer|March 24, 2021
Stereotactic radiotherapy for oligoprogressive ER-positive breast cancer (AVATAR)Reem Alomran, Michelle White, Melissa Bruce, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 22, 2012
TGF-β blockade improves the distribution and efficacy of therapeutics in breast carcinoma by normalizing the tumor stromaJieqiong Liu, Shan Liao, Benjamin Diop-Frimpong, et al.
Translational Oncology|November 23, 2020
Enhanced toxicity with CDK 4/6 inhibitors and palliative radiotherapy: Non-consecutive case series and review of the literatureSteven David, Gwo Ho, Daphne Day, et al.
Pageof 7